Kintara Therapeutics (NASDAQ: KTRA)
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-27 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.110 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.
Other companies in Kintara Therapeutics’s space includes: Allena Pharma (NASDAQ:ALNA), Biocept (NASDAQ:BIOC), Indaptus Therapeutics (NASDAQ:INDP), TransCode Therapeutics (NASDAQ:RNAZ) and CohBar (NASDAQ:CWBR).
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Dawson James on Monday, May 16, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $0.255 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Kintara Therapeutics.
Kintara Therapeutics’s Q4 earnings are confirmed for Tuesday, September 27, 2022.
There is no upcoming split for Kintara Therapeutics.
Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.